


# Information for people switching from Eviplera® to generic emtricitabine/tenofovir disoproxil with Edurant® (rilpivirine)



Eviplera® is the brand name of the medication you are taking which contains the active drugs emtricitabine, tenofovir disoproxil and rilpivirine. You are being asked to switch from Eviplera to two separate tablets containing the same active ingredients: generic emtricitabine with tenofovir disproxil and Edurant (rilpivirine). Edurant is the brand name containing the active drug rilpivirine which is also contained in Eviplera.

### What is a 'generic' drug?

When a drug company makes a new medicine, it is controlled under a patent. It has an approved, or generic name, as well as its own brand name, chosen by the company. For example ibuprofen is the generic name and Nurofen<sup>®</sup> is the brand name. Once the patent runs out, other drug companies can make the drug at a lower cost. These are called 'generic' drugs. The NHS always tries to use generic drugs. This is normal practice for most health conditions. If you are on medications prescribed by your GP for another condition, you may have always been prescribed generic drugs or been switched to generic drugs in the past, as it is standard procedure within the NHS.

# Will generic emtricitabine/tenofovir disoproxil and Edurant work the same way as Eviplera?

Yes. They should all work in in the same way as Eviplera as long both tablets (emtricitabine/tenofovir disoproxil and Edurant) are taken **together** with a **meal**.

### What will the new emtricitabine/tenofovir disoproxil and Edurant tablets look like?

Emtricitabine with tenofovir disoproxil is a generic medicine therefore the colour and shape of these tablets may change from time to time depending on which generic manufacturer your clinic is using. This is why it is so important to read the packaging and the label. Edurant is a round white film-coated tablet with a diameter with "TMC" on one side and "25" on the other side.

### Will there be any side effects when I switch?

You shouldn't experience any side effects when you switch as the active drugs are the same. Occasionally some people may experience some minor side effects when they take a new formulation of a drug, however these should settle quickly. Please speak to your doctor, pharmacist or nurse if you experience any new side effects.

### How do I take emtricitabine/tenofovir disoproxil and Edurant?

- As soon as your Eviplera runs out you should then switch to the emtricitabine/tenofovir disoproxil and Edurant tablets.
- Both tablets should be taken together at the same time every day
- Edurant should be taken with a meal to make sure you absorb rilpivirine properly, however a nutritional drink or protein-rich drink on its own should not be considered a meal in this instance.
- Interactions with other medicines: Both emtricitabine/tenofovir disoproxil and Edurant can interact with other medicines, herbal, complementary or over the counter medicines that you might buy. In particular medicines such as indigestion remedies and drugs that affect stomach acid. It is important that you tell the doctor, pharmacist or nurse about any medicines you are taking so that they can check that they are compatible. Make sure you read the patient information leaflet you received with your HIV medicines for a full list.

If you have any questions about emtricitabine/tenofovir disoproxil and Edurant please contact your clinic doctor, pharmacist or nurse.

## **Contact:**

# **Telephone number:**

This leaflet was produced by the HIV Pharmacy Association (HIVPA). This leaflet does not replace the patient information leaflet issued with the product, but should be read in conjunction with it. This leaflet should only be distributed to people already established on Eviplera who are planning to switch to emtricitabine/tenofovir disoproxil and Edurant tablets. This leaflet does not constitute any endorsement of the use of products discussed by HIVPA and is intended for information purposes only. This leaflet is only designed for use with the United Kingdom and Ireland and is covered by the Terms and Conditions of the HIVPA website. Created February 2022.